Published in Recent Pat Anticancer Drug Discov on November 01, 2008
Analysis of genetic copy number changes in cervical disease progression. BMC Cancer (2010) 0.85
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med (2004) 6.40
The cellular geography of aurora kinases. Nat Rev Mol Cell Biol (2003) 6.40
Aurora-A - a guardian of poles. Nat Rev Cancer (2005) 4.11
AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell (2003) 3.50
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res (2007) 3.20
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Aurora kinases as anticancer drug targets. Clin Cancer Res (2008) 2.92
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
Validating Aurora B as an anti-cancer drug target. J Cell Sci (2006) 2.30
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res (2007) 2.16
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08
Aurora kinases: new targets for cancer therapy. Clin Cancer Res (2006) 1.85
Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle (2009) 1.82
MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol (2007) 1.79
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res (2004) 1.75
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther (2007) 1.67
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A (2010) 1.65
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther (2010) 1.48
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood (2007) 1.46
Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol Biol Cell (2004) 1.43
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem (2009) 1.39
Aurora kinases as targets for cancer therapy. Cancer Treat Rev (2007) 1.33
High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther (2007) 1.30
AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res (2009) 1.30
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther (2009) 1.27
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica (2008) 1.25
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res (2008) 1.23
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem (2006) 1.22
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood (2008) 1.18
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck (2009) 1.17
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood (2009) 1.16
Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev (2010) 1.15
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer (2010) 1.15
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med (2008) 1.15
Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett (2008) 1.15
Mitotic drivers--inhibitors of the Aurora B Kinase. Cancer Metastasis Rev (2009) 1.14
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res (2012) 1.13
MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res (2010) 1.11
Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett (2007) 1.09
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res (2005) 1.09
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res (2010) 1.08
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer (2005) 1.07
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther (2010) 1.07
Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma (2008) 1.07
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res (2008) 1.04
The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett (2009) 1.04
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol (2007) 1.01
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 1.01
The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol (2009) 0.99
Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol (2009) 0.99
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem J (2009) 0.98
VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res (2010) 0.98
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res (2010) 0.98
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia (2009) 0.98
The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther (2009) 0.97
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol (2010) 0.97
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer (2008) 0.97
Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle (2009) 0.96
The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle (2009) 0.94
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol (2009) 0.93
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol (2010) 0.93
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther (2010) 0.91
The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther (2010) 0.91
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol (2008) 0.90
ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology (2009) 0.88
Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncol (2007) 0.88
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. Pharmacogenomics J (2009) 0.88
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol (2010) 0.86
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol (2010) 0.84
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. Cancer Sci (2008) 0.81
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Invest New Drugs (2015) 0.80
Aurora kinases. Curr Biol (2008) 0.79
Aurora kinase targeted therapeutics in oncology: past, present and future. Expert Opin Drug Discov (2007) 0.78
Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer (2010) 0.76
DNA repair. J Thorac Oncol (2009) 0.75
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Electric-field control of local ferromagnetism using a magnetoelectric multiferroic. Nat Mater (2008) 7.23
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med (2009) 3.80
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Syphilis among female sex workers in southwestern China: potential for HIV transmission. Sex Transm Dis (2006) 2.34
Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.34
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
New perspectives on host-parasite interplay by comparative transcriptomic and proteomic analyses of Schistosoma japonicum. PLoS Pathog (2006) 2.12
Anticancer therapy targeting the apoptotic pathway. Lancet Oncol (2003) 2.06
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Global public health implications of a mass gathering in Mecca, Saudi Arabia during the midst of an influenza pandemic. J Travel Med (2010) 2.00
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
Ethics guidelines for research with the recently dead. Nat Med (2005) 1.56
An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol (2004) 1.52
A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of lung cancer. Lung Cancer (2011) 1.47
The kiss/kissr systems are dispensable for zebrafish reproduction: evidence from gene knockout studies. Endocrinology (2014) 1.46
Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Exp Neurol (2008) 1.44
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
Intra-aortic balloon pump improves clinical prognosis and attenuates C-reactive protein level in acute STEMI complicated by cardiogenic shock. Cardiology (2010) 1.41
Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis (2002) 1.39
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res (2005) 1.39
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer (2011) 1.37
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res (2003) 1.35
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34
Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med (2005) 1.33
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P. FASEB J (2006) 1.30
A flexible and highly pressure-sensitive graphene-polyurethane sponge based on fractured microstructure design. Adv Mater (2013) 1.30
PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget (2012) 1.30
Risk of lung cancer associated with domestic use of coal in Xuanwei, China: retrospective cohort study. BMJ (2012) 1.30
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol (2012) 1.27
Excretory/secretory proteome of the adult developmental stage of human blood fluke, Schistosoma japonicum. Mol Cell Proteomics (2009) 1.27
Children's respiratory morbidity prevalence in relation to air pollution in four Chinese cities. Environ Health Perspect (2002) 1.27
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res (2012) 1.27
Tuberculosis infection in the United States: national trends over three decades. Am J Respir Crit Care Med (2007) 1.27
The genomic determinants of alcohol preference in mice. Mamm Genome (2008) 1.26
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26
A simple method to isolate salt-tolerant myxobacteria from marine samples. J Microbiol Methods (2002) 1.26
Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2010) 1.25
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer (2006) 1.25
Silver nanowire percolation network soldered with graphene oxide at room temperature and its application for fully stretchable polymer light-emitting diodes. ACS Nano (2014) 1.25
Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes. J Invest Dermatol (2007) 1.23
Entry and exit screening of airline travellers during the A(H1N1) 2009 pandemic: a retrospective evaluation. Bull World Health Organ (2013) 1.22
Research gaps for three main tropical diseases in the People's Republic of China. Infect Dis Poverty (2013) 1.21
Genome-wide identification of Schistosoma japonicum microRNAs using a deep-sequencing approach. PLoS One (2009) 1.20
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol (2008) 1.19
IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation. Proc Natl Acad Sci U S A (2013) 1.19
Co-infections with Babesia microti and Plasmodium parasites along the China-Myanmar border. Infect Dis Poverty (2013) 1.18
Extraordinary expansion of a Sorangium cellulosum genome from an alkaline milieu. Sci Rep (2013) 1.18
Continued spread of HIV among injecting drug users in southern Sichuan Province, China. Harm Reduct J (2007) 1.16
Transcriptomics tool for the human Schistosoma blood flukes using microarray gene expression profiling. Exp Parasitol (2006) 1.16
Retracted Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity (2003) 1.15
A prototype MR insertable brain PET using tileable GAPD arrays. Med Phys (2013) 1.15
Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc Natl Acad Sci U S A (2011) 1.15
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res (2003) 1.15
Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis (2011) 1.15
Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther (2004) 1.15
Early identification and treatment of PV re-connections: role of observation time and impact on clinical results of atrial fibrillation ablation. Europace (2007) 1.13
PTX cruiser: driving autoimmunity via TLR4. Trends Immunol (2005) 1.12
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol (2008) 1.11
Multiple near-identical genotypes of Schistosoma japonicum can occur in snails and have implications for population-genetic analyses. Int J Parasitol (2008) 1.11
Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers. Carcinogenesis (2010) 1.10
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol (2004) 1.10
Protein-functionalized synthetic antiferromagnetic nanoparticles for biomolecule detection and magnetic manipulation. Angew Chem Int Ed Engl (2009) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
TEM analyses of synthetic anti-ferromagnetic (SAF) nanoparticles fabricated using different release layers. Ultramicroscopy (2008) 1.09
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol (2002) 1.09
Cloning and characterization of a mouse endoplasmic reticulum alkaline ceramidase: an enzyme that preferentially regulates metabolism of very long chain ceramides. J Biol Chem (2003) 1.09
Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res (2005) 1.08
Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer (2005) 1.08
Cytoplasmic impact on cross-genus cloned fish derived from transgenic common carp (Cyprinus carpio) nuclei and goldfish (Carassius auratus) enucleated eggs. Biol Reprod (2004) 1.07
Overexpression of the wheat aquaporin gene, TaAQP7, enhances drought tolerance in transgenic tobacco. PLoS One (2012) 1.06
Cellular microRNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells. J Cell Mol Med (2012) 1.06
Household air pollution and lung cancer in China: a review of studies in Xuanwei. Chin J Cancer (2014) 1.05
Clonorchis sinensis: development and evaluation of a nested polymerase chain reaction (PCR) assay. Exp Parasitol (2006) 1.05
Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res (2012) 1.05
Food and botanical groupings and risk of breast cancer: a case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev (2005) 1.05
Genome-wide identification and analysis of MAPK and MAPKK gene families in Brachypodium distachyon. PLoS One (2012) 1.05
Probing cellular traction forces by micropillar arrays: contribution of substrate warping to pillar deflection. Nano Lett (2010) 1.04
Substrate specificity, membrane topology, and activity regulation of human alkaline ceramidase 2 (ACER2). J Biol Chem (2010) 1.03
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol (2003) 1.03
Surgical treatment of primary duodenal adenocarcinoma. Hepatogastroenterology (2006) 1.03
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol (2010) 1.03
The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem (2013) 1.03
Understanding rice plant resistance to the Brown Planthopper (Nilaparvata lugens): a proteomic approach. Proteomics (2009) 1.03